Summary & Overview

CPT 0356U: NavDx® HPV Cell‑free DNA Test for Cancer Recurrence

Headline: New CPT code 0356U identifies NavDx® cell–free DNA test for HPV‑associated cancer surveillance

Lead: CPT code 0356U designates NavDx®, a proprietary laboratory assay that evaluates cell–free DNA from oropharyngeal or anal specimens for 17 human papillomavirus (HPV)–related DNA biomarkers and provides an algorithmic assessment of cancer recurrence risk. The code formalizes billing for a single-vendor molecular test increasingly used in post‑treatment surveillance.

Why it matters: Adoption of CPT code 0356U standardizes claims reporting for a targeted circulating tumor DNA test tied to HPV‑associated cancers, with implications for coverage, utilization tracking, and comparative benchmark analyses across national payers.

Payers covered: Analysis addresses national payers including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

What readers will learn: This publication summarizes the clinical context for CPT code 0356U, expected sites of service, and how the test is reported in claims. Readers will find an overview of payer coverage considerations, common billing practices, and the role of proprietary laboratory analyses in cancer surveillance. The report outlines available benchmarks and policy updates where applicable and highlights clinical implications for post‑treatment monitoring of HPV‑associated malignancies.

Scope: National coverage; data-driven benchmarks and payer policy summaries where available. Data not available in the input is identified explicitly.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicare0356UCPTProprietary Laboratory AnalysesNavDxHPVcell-free DNAmolecular diagnosticscancer surveillanceoropharyngealanal

Billing Code Overview

CPT code 0356U is a Proprietary Laboratory Analyses (PLA) code that applies exclusively to a single laboratory test: NavDx® by Naveris Inc. The test analyzes cell–free DNA from an oropharyngeal or anal specimen to detect 17 DNA biomarkers associated with human papillomavirus–associated cancer. An algorithmic result indicates the likelihood of cancer recurrence following treatment, supporting surveillance and clinical decision-making.

Service Type: Clinical laboratory molecular diagnostic testing using cell–free DNA analysis with algorithmic interpretation.

Typical Site of Service: Clinical laboratories and outpatient specimen collection sites where oropharyngeal or anal specimens are obtained and sent for proprietary laboratory analysis.

Clinical & Coding Specifications

Clinical Context

A 58-year-old patient with a history of oropharyngeal squamous cell carcinoma treated with definitive chemoradiation presents for routine surveillance. The treating head and neck oncologist orders NavDx® to evaluate cell-free HPV DNA from an oropharyngeal swab to assess for molecular evidence of residual disease or early recurrence. The clinical workflow: sample collection of an oropharyngeal or anal swab in the clinic, proper labeling and courier transport to the proprietary laboratory (Naveris Inc.), laboratory extraction and targeted sequencing of cell‑free DNA for 17 HPV‑related DNA biomarkers, algorithmic risk scoring for recurrence, and return of the report to the ordering clinician. Results are used as an adjunct to clinical exam, imaging, and endoscopy during post‑treatment surveillance to stratify recurrence risk and guide subsequent diagnostic imaging or biopsy decisions.

Coding Specifications

Modifier	Description	When to Use
`26`	Professional component	Use when billing only the physician interpretation component separate from the laboratory technical component if applicable and allowed.
`TC`	Technical component	Use when billing only the laboratory technical component of the test when the performing lab bills separately.

Taxonomy Code	Specialty	Notes
`2084P0300X`	Medical Oncology	Oncologists commonly order surveillance molecular assays for HPV‑associated cancers.
`207R00000X`	Otolaryngology (ENT)	Head and neck surgeons collect oropharyngeal specimens and manage surveillance.
`2085R0202X`	Hematology & Oncology	Specialists involved in post‑treatment surveillance and interpretation of lab results.
`363L00000X`	Clinical Laboratory	Laboratory directors and pathologists oversee testing and reporting of proprietary assays.
`207K00000X`	Radiation Oncology	Radiation oncologists participate in surveillance and may order molecular testing.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C01.9`	Malignant neoplasm of base of tongue, unspecified	Oropharyngeal primary site commonly associated with HPV‑related cancers monitored with NavDx®.
`C09.0`	Malignant neoplasm of tonsillar pillar	Tonsillar cancers are frequent HPV‑associated oropharyngeal tumors for which cfDNA surveillance is relevant.
`C10.9`	Malignant neoplasm of oropharynx, unspecified	General oropharyngeal cancer diagnosis where molecular monitoring for recurrence is used.
`C21.9`	Malignant neoplasm of anus and anal canal, unspecified	Anal squamous cell carcinoma is HPV‑associated and may be monitored using or anal specimen testing for HPV cfDNA.
`Z85.028`	Personal history of malignant neoplasm of oropharynx	History of disease status used to justify surveillance molecular testing.
`Z85.038`	Personal history of malignant neoplasm of anus and anal canal	Prior anal cancer surveillance coding justification for periodic molecular testing.
`R92.8`	Other abnormal and inconclusive findings on diagnostic imaging of breast — not typically used; included as placeholder	Not directly relevant; omit in payer adjudication unless clinically justified.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`87624`	Infectious agent detection by nucleic acid (DNA or RNA); human papillomavirus, high‑risk types, direct probe technique	May be performed as an alternative or complementary HPV nucleic acid test in diagnostic workflows.
`87498`	Infectious agent detection by nucleic acid (DNA or RNA), multiple organisms, amplified probe technique; multiplex	May accompany specimen processing when broader molecular panels for pathogens or variants are ordered.
`88172`	Cytopathology, concentration technique; single specimen	May be billed when cytologic evaluation of a swab or brush specimen is performed alongside molecular testing.
`88305`	Level IV surgical pathology, gross and microscopic exam	May be billed for biopsy specimens if molecular test prompts tissue sampling to confirm recurrence.
`87500`	Infectious agent detection by nucleic acid (DNA or RNA); Clostridioides difficile	Example of other molecular pathogen tests that may be run in molecular laboratories; not directly related but often listed in molecular test panels.